June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Systemic metformin use reduces open-angle glaucoma risk
Author Affiliations & Notes
  • Joëlle Vergroesen
    Ophthalmology, Erasmus Medical Center, Rotterdam, Netherlands
    Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands
  • Bruno HC Stricker
    Pharmaco-epidemiology, Erasmus Medical Center, Netherlands
  • Arfan M Ikram
    Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands
  • Maryam Kavousi
    Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands
  • Albert Hofman
    Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands
  • Caroline Klaver
    Ophthalmology/Epidemiology, Erasmus Medical Center, Netherlands
    Ophthalmology, Radboud University Medical Center, Netherlands
  • Wishal Ramdas
    Ophthalmology, Erasmus Medical Center, Rotterdam, Netherlands
  • Footnotes
    Commercial Relationships   Joëlle Vergroesen, None; Bruno Stricker, None; Arfan Ikram, None; Maryam Kavousi, None; Albert Hofman, None; Caroline Klaver, None; Wishal Ramdas, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 656. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joëlle Vergroesen, Bruno HC Stricker, Arfan M Ikram, Maryam Kavousi, Albert Hofman, Caroline Klaver, Wishal Ramdas; Systemic metformin use reduces open-angle glaucoma risk. Invest. Ophthalmol. Vis. Sci. 2020;61(7):656.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The use of metformin, commonly prescribed in patients with Diabetes Mellitus type 2 (T2DM), leads to downstream inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). NF-κB activation in glial cells promotes neuronal cell death. Thus, metformin may possess neuroprotective properties in the development of open-angle glaucoma (OAG). The aim of the current study is to explore the associations of metformin with OAG.

Methods : Longitudinal data of three prospective population-based cohort studies (Rotterdam Study[RS]-I, RS-II, RS-III) were analyzed. Participants, aged ≥45 years with no OAG at baseline, were regularly monitored for incident OAG. Information on metformin use was obtained through continuous registration by pharmacies during the entire study period. The association of metformin with intraocular pressure (IOP) and incident OAG was analyzed using multivariate linear regression analyses and Cox proportional hazards models, respectively. Both analyses were adjusted for age, sex, BMI and use of statins and anti-hypertensive medication.

Results : During a mean follow-up of 10.1±5.4 years, 210 (2.5%) of 8,529 participants developed OAG; metformin was used by 492 (5.8%) participants. Metformin use was significantly associated with elevated IOP in participants using >2g/day/year (Beta with corresponding 95% confidence interval [CI]: 0.544 [0.08-1.01]). T2DM by itself was not associated with IOP. Use of metformin was associated with reduced risk of developing OAG in the entire group (hazard ratio (HR) [95% CI]: 0.35 [0.14-0.85]) and in participants with T2DM (HR [95% CI]: 0.16 [0.05-0.49]), respectively. We observed a trend towards a reduced risk with prolonged use in both groups (HR [95% CI]: 0.83 [0.69-1.00] and HR [95% CI]: 0.74 [0.59-0.93], respectively).

Conclusions : Systemic use of metformin was associated with a reduced risk of OAG, in a duration-dependent manner; this could not be explained by IOP. Thus, mechanisms beyond IOP regulation may be involved in the metformin-induced OAG risk-reduction.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×